Abstract: The present invention relates to methods and compositions for modulating levels of amyloid-? peptide (A?) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of A? levels via selective modulation (e.g., inhibition) of ?-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A?-related disorder, by administering a compound that results in the modulation of ?-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain A? disorder, such as Alzheimer's disease.

Abstract: The present invention relates to methods and compositions for modulating levels of amyloid-? peptide (A?) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of A? levels via selective modulation (e.g., inhibition) of ?-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A?-related disorder, by administering a compound that results in the modulation of ?-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain A? disorder, such as Alzheimer's disease.

Abstract: The present invention relates to methods and compositions for modulating levels of amyloid-? peptide (A?) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of A? levels via selective modulation (e.g., inhibition) of ?-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A?-related disorder, by administering a compound that results in the modulation of ?-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain A? disorder, such as Alzheimer's disease.

Abstract: The present invention relates to identification of cellular components, genotypes and gene expression profiles associated with mood disorders. In some embodiments, the present invention relates to the correlation between ribosomal protein S6 (RPS6) and depression and/or anxiety. Embodiments of the present invention further relate to regulation of the activity of RPS6, e.g., by p90 Ribosomal S6 protein kinase. Embodiments of the present invention provide methods and compositions for, e.g., diagnosing, treating, and monitoring depression and/or anxiety, or risk thereof, and for selecting, monitoring, and tailoring treatments for depression and/or anxiety.

Abstract: The present invention relates to methods and compositions for modulating levels of amyloid-? peptide (A?) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of A? levels via selective modulation (e.g., inhibition) of ?-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A?-related disorder, by administering a compound that result in the modulation of ?-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain A? disorder, such as Alzheimer's disease.